PriceTargets.com logo

Viking Therapeutics - VKTX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $106.75
  • Forecasted Upside: 152.66%
  • Number of Analysts: 13
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 11 Buy Ratings
  • 2 Strong Buy Ratings
$42.25 As of 12/20/2024 06:45 PM ET
▲ +0.76 (1.83%)

This chart shows the closing price for VKTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Viking Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VKTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VKTX

Analyst Price Target is $106.75
▲ +152.66% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Viking Therapeutics in the last 3 months. The average price target is $106.75, with a high forecast of $138.00 and a low forecast of $74.00. The average price target represents a 152.66% upside from the last price of $42.25.

This chart shows the closing price for VKTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 13 contributing investment analysts is to buy stock in Viking Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 1 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 1 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 2 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 2 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/18/2024HC WainwrightReiterated RatingBuy ➝ Buy$102.00 ➝ $102.00
12/2/2024Piper SandlerInitiated CoverageOverweight$74.00
11/26/2024HC WainwrightReiterated RatingBuy ➝ Buy$102.00 ➝ $102.00
11/22/2024B. RileyInitiated CoverageBuy$109.00
11/21/2024B. RileyUpgradeStrong-Buy
11/20/2024William BlairReiterated RatingOutperform
11/4/2024HC WainwrightBoost TargetBuy ➝ Buy$90.00 ➝ $102.00
10/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$90.00 ➝ $90.00
10/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$90.00 ➝ $90.00
9/25/2024OppenheimerReiterated RatingOutperform ➝ Outperform$138.00 ➝ $138.00
9/12/2024Morgan StanleyReiterated RatingOverweight ➝ Overweight$105.00 ➝ $105.00
9/11/2024JPMorgan Chase & Co.Initiated CoverageOverweight$80.00
7/25/2024Raymond JamesBoost TargetStrong-Buy ➝ Strong-Buy$116.00 ➝ $118.00
7/25/2024HC WainwrightReiterated RatingBuy ➝ Buy$90.00 ➝ $90.00
6/27/2024Morgan StanleyInitiated CoverageOverweight$105.00
6/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$90.00 ➝ $90.00
6/17/2024Truist FinancialReiterated RatingBuy ➝ Buy$120.00 ➝ $120.00
6/4/2024Raymond JamesReiterated RatingStrong-Buy
6/4/2024Maxim GroupReiterated RatingBuy ➝ Buy$120.00 ➝ $120.00
6/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$90.00 ➝ $90.00
5/16/2024Raymond JamesUpgradeOutperform ➝ Strong-Buy$115.00 ➝ $116.00
5/16/2024Truist FinancialReiterated RatingBuy ➝ Buy$120.00
4/25/2024HC WainwrightReiterated RatingBuy ➝ Buy$90.00
3/26/2024OppenheimerBoost TargetOutperform ➝ Outperform$116.00 ➝ $138.00
3/26/2024BTIG ResearchBoost TargetBuy ➝ Buy$100.00 ➝ $125.00
3/26/2024HC WainwrightReiterated RatingBuy ➝ Buy$90.00
3/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$90.00
3/15/2024Maxim GroupReiterated RatingBuy ➝ Buy$120.00
3/15/2024BTIG ResearchBoost TargetBuy ➝ Buy$86.00 ➝ $100.00
3/15/2024Stifel NicolausReiterated RatingBuy ➝ Buy$80.00
3/7/2024Jefferies Financial GroupInitiated CoverageBuy$110.00
2/29/2024Truist FinancialBoost TargetBuy ➝ Buy$32.00 ➝ $120.00
2/28/2024OppenheimerBoost TargetOutperform ➝ Outperform$46.00 ➝ $116.00
2/27/2024Raymond JamesBoost TargetOutperform ➝ Outperform$37.00 ➝ $115.00
2/27/2024HC WainwrightBoost TargetBuy ➝ Buy$33.00 ➝ $90.00
2/23/2024William BlairReiterated RatingOutperform
2/14/2024Stifel NicolausBoost TargetBuy ➝ Buy$30.00 ➝ $35.00
2/8/2024Maxim GroupBoost TargetBuy ➝ Buy$35.00 ➝ $50.00
12/4/2023Truist FinancialReiterated RatingBuy ➝ Buy$32.00
10/2/2023Truist FinancialReiterated RatingBuy ➝ Buy$32.00
8/8/2023Stifel NicolausReiterated RatingBuy$30.00
5/30/2023Roth CapitalReiterated RatingBuy
5/17/2023Raymond JamesBoost Target$35.00 ➝ $37.00
5/16/2023Stifel NicolausBoost Target$25.00 ➝ $30.00
4/27/2023HC WainwrightBoost Target$21.00 ➝ $33.00
4/25/2023OppenheimerBoost Target$30.00 ➝ $35.00
3/29/2023Roth MkmBoost TargetBuy$15.00 ➝ $19.00
3/29/2023Truist FinancialBoost TargetBuy$28.00 ➝ $32.00
3/29/2023Raymond JamesBoost TargetOutperform$12.00 ➝ $35.00
3/28/2023Stifel NicolausBoost TargetBuy$22.00 ➝ $25.00
3/28/2023BTIG ResearchBoost TargetBuy$20.00 ➝ $31.00
3/28/2023OppenheimerBoost TargetOutperform$20.00 ➝ $30.00
3/28/2023Maxim GroupBoost TargetBuy$15.00 ➝ $25.00
3/16/2023Stifel NicolausInitiated CoverageBuy$22.00
2/23/2023OppenheimerBoost Target$17.00 ➝ $20.00
2/9/2023HC WainwrightReiterated RatingBuy$21.00
2/9/2023Raymond JamesBoost TargetOutperform$11.00 ➝ $12.00
12/19/2022Maxim GroupBoost TargetBuy$10.00 ➝ $15.00
11/1/2022OppenheimerLower Target$10.00
10/27/2022Raymond JamesBoost TargetOutperform$10.00 ➝ $11.00
4/28/2022Roth CapitalLower Target$20.00 ➝ $15.00
2/10/2022Raymond JamesLower TargetOutperform$13.00 ➝ $10.00
11/12/2021Maxim GroupInitiated CoverageBuy$14.00
11/8/2021BMO Capital MarketsReiterated RatingBuy$15.00
11/3/2021Leerink PartnersReiterated RatingOutperform
10/29/2021William BlairReiterated RatingBuy
7/29/2021Raymond JamesBoost TargetOutperform$12.00 ➝ $13.00
6/20/2021Leerink PartnersInitiated CoverageBuy$18.00
6/18/2021B. RileyReiterated RatingBuy$15.00
6/17/2021HC WainwrightReiterated RatingBuy$21.00
5/25/2021Raymond JamesDowngradeStrong-Buy ➝ Outperform$27.00 ➝ $12.00
5/3/2021Leerink PartnersReiterated RatingBuy$18.00
1/22/2021Stifel NicolausReiterated RatingBuy$13.00
10/29/2020Raymond JamesBoost TargetStrong-Buy$25.00 ➝ $27.00
9/11/2020William BlairReiterated RatingBuy
9/10/2020B. RileyReiterated RatingBuy$15.00
9/1/2020BTIG ResearchBoost TargetBuy$9.00 ➝ $12.00
8/31/2020Chardan CapitalBoost TargetBuy$15.00 ➝ $20.00
8/28/2020HC WainwrightBoost TargetBuy$18.00 ➝ $21.00
8/6/2020Raymond JamesReiterated RatingBuy$25.00
7/30/2020B. RileyReiterated RatingBuy$12.00
7/29/2020Chardan CapitalReiterated RatingBuy$15.00
7/29/2020OppenheimerReiterated RatingBuy$12.00
7/29/2020Stifel NicolausReiterated RatingBuy$14.00
6/4/2020BMO Capital MarketsInitiated CoverageOutperform$14.00
5/5/2020Chardan CapitalInitiated CoverageBuy$15.00
5/4/2020B. RileyLower TargetBuy$16.00 ➝ $12.00
5/2/2020Maxim GroupInitiated CoverageBuy$14.00
5/1/2020OppenheimerInitiated CoverageBuy$12.00
5/1/2020Raymond JamesLower TargetStrong-Buy$41.00 ➝ $25.00
5/1/2020BTIG ResearchInitiated CoverageBuy$9.00
4/30/2020Stifel NicolausReiterated RatingBuy$14.00
4/3/2020William BlairReiterated RatingBuy
3/18/2020William BlairReiterated RatingBuy
2/27/2020HC WainwrightLower TargetBuy$31.00 ➝ $18.00
1/2/2020Leerink PartnersReiterated RatingOutperform
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.90 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 32 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 27 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 32 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
7/24/2024
  • 37 very positive mentions
  • 38 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 41 very positive mentions
  • 32 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 29 very positive mentions
  • 39 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 43 very positive mentions
  • 47 positive mentions
  • 7 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 53 very positive mentions
  • 37 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 53 very positive mentions
  • 37 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Viking Therapeutics logo
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $42.25
Low: $41.97
High: $45.00

50 Day Range

MA: $58.05
Low: $38.28
High: $78.03

52 Week Range

Now: $42.25
Low: $17.23
High: $99.41

Volume

8,815,748 shs

Average Volume

4,483,956 shs

Market Capitalization

$4.71 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88

Frequently Asked Questions

What sell-side analysts currently cover shares of Viking Therapeutics?

The following Wall Street sell-side analysts have issued reports on Viking Therapeutics in the last twelve months: B. Riley, BTIG Research, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Maxim Group, Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Stifel Nicolaus, StockNews.com, Truist Financial Co., and William Blair.
View the latest analyst ratings for VKTX.

What is the current price target for Viking Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Viking Therapeutics in the last year. Their average twelve-month price target is $106.75, suggesting a possible upside of 152.7%. Oppenheimer Holdings Inc. has the highest price target set, predicting VKTX will reach $138.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $74.00 for Viking Therapeutics in the next year.
View the latest price targets for VKTX.

What is the current consensus analyst rating for Viking Therapeutics?

Viking Therapeutics currently has 11 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VKTX will outperform the market and that investors should add to their positions of Viking Therapeutics.
View the latest ratings for VKTX.

What other companies compete with Viking Therapeutics?

Other companies that are similar to Viking Therapeutics include Teva Pharmaceutical Industries, BeiGene, Moderna, Viatris and Summit Therapeutics. Learn More about companies similar to Viking Therapeutics.

How do I contact Viking Therapeutics' investor relations team?

Viking Therapeutics' physical mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The biotechnology company's listed phone number is (858) 704-4660 and its investor relations email address is [email protected]. The official website for Viking Therapeutics is www.vikingtherapeutics.com. Learn More about contacing Viking Therapeutics investor relations.